Longboard Pharmaceuticals, Inc. (LBPH)
Last Price$60.00.0%
Market Cap$2,336.7M
LBPH Rating
LBPH Quality rating performance
LBPH Intrinsic Value
Key Highlights:
As of Dec 13, 2024 LBPH Relative Value is $11.2, which is overvalued by 81.4%, compared to current share price of $60.0.
As of Dec 13, 2024 LBPH DCF Value is N/A, which is undervalued by N/A, compared to current share price of $60.0.
LBPH Share Price History
1W 0.0%
1M 0.3%
6M 200.7%
YTD 139.0%
1Y 1,170.8%
3Y 943.1%
5Y 260.2%
10Y 260.2%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
LBPH Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$2,336.7M
$2,052.0M
$8,000.0
($65.9M)
Shares Outstanding
39M
Employees
N/A
Growth (CAGR)
N/A
N/A
(6.87%)
Profitability
50.0%
(1,093,125.0%)
(954,300.0%)
(824,137.5%)
(824,137.5%)
86.4%
Intrinsic Value
$11.2 (81.3% overvalued)
N/A
$11.2
($17.1)
($0.2)
(100.0%)
(104.9%)
Valuation (LTM)
Return on Capital
(26.8%)
(25.0%)
(4,363.8%)
(30.1%)
(19.0%)
(12,555.5%)
(12,555.5%)
Financial Health
($284.7M)
4.3x
(172.8x)
Dividends
Earnings
Jan 01, 1970
MISS by 0.0%
MISS by 6.3%
(5.1%)
3 Beat & 7 Miss
LBPH Stock Financials
LBPH Income Statement Metrics
Annual
Quarterly
LTM
LBPH Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($50.9M) +33.6% YoY
Capital Expenditure (CAPEX)
$0.0 N/A YoY
Free Cash Flow (FCF)
($50.9M) +33.6% YoY
LBPH Income Statement Overview
Annual
Quarterly
LTM
Dec'20
Dec'21
Dec'22
Dec'23
LBPH Balance Sheet Overview
Annual
Quarterly
LTM
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$50.7M
Current assets ($50.2M, 99.1% of total)
$48.5M (95.7%)
$0.0 (0.0%)
Other current assets
$1,723.0K (3.4%)
Non-current assets ($476.0K, 0.9% of total)
$0.0 (0.0%)
$476.0K (0.9%)
$0.0 (0.0%)
Other non-current assets
$0.0 (0.0%)
Financial position
($48.0M)
Cash & Short-term
Investments
Total Debt
LBPH Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
LBPH Earnings Surprises
Crunching data... Almost there!
LBPH Dividends
LBPH Dividend Yield
Crunching data... Almost there!
LBPH Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with LBPH
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$2,336.7M | 5.9 | $11.2 81.3% overvalued | 1,170.8% | $8,000.0 | ($65.9M) | N/A | (824,137.5%) | 50.0% | (4,363.8%) | 1.4% | |
$124.8B | 5.7 | $187.5 61.6% overvalued | 17.8% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$77.0B | 6.3 | $1,048.3 46.0% undervalued | (25.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$34.4B | 5.8 | $123.0 78.8% overvalued | 50.8% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$30.7B | 5.2 | $91.8 61.6% overvalued | 60.1% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.0B | 5.9 | $191.1 94.2% undervalued | 2.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.5B | 5.4 | $71.6 120.5% undervalued | 11.2% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$13.8B | 7.7 | $542.2 78.1% undervalued | 22.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.4B | 6.7 | $46.9 33.5% overvalued | (18.0%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$13.3B | 5.9 | $0.6 96.9% overvalued | 330.2% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.5 | $2,745.6 1,111.0% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
FAQ
What is Longboard Pharmaceuticals, Inc. (LBPH) stock rating?
As of today, Longboard Pharmaceuticals, Inc. has a stock rating of 6 (out of 10), which is considered Good.
is Longboard Pharmaceuticals, Inc. (LBPH) a good stock to buy?
As of today, Longboard Pharmaceuticals, Inc. has a Good stock rating, which is 81.3% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.